ORIC Pharmaceuticals Announces Collaboration with Janssen to Advance First-Line Treatment for EGFR Exon 20 Mutated NSCLC

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical-stage oncology company specializing in therapies addressing therapeutic resistance, has entered into a supply agreement with Janssen Research & Development, LLC, a Johnson & Johnson company. The collaboration focuses on evaluating ORIC-114, a brain-penetrant, orally bioavailable, irreversible EGFR/HER2 inhibitor, in combination with Janssen’s fully-human EGFR-MET bispecific antibody, SC amivantamab, as a first-line treatment for advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.

Under the agreement, ORIC will conduct and sponsor the Phase 1b trial, with Janssen supplying SC amivantamab. ORIC retains development and commercialization rights to ORIC-114 and can explore its potential in combination with other agents.

This partnership builds on ORIC’s recent progress in the monotherapy dose escalation portion of its Phase 1b trial, which established provisional RP2D levels of ORIC-114 at 80 mg and 120 mg QD. The company is currently optimizing doses in NSCLC patients with EGFR exon 20, HER2 exon 20, or atypical EGFR mutations.

ORIC’s collaboration with Janssen highlights the company’s commitment to advancing precision therapies and addressing unmet needs in oncology.